Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva - Full Text View

Sponsored by:	The Cleveland Clinic
Information provided by:	The Cleveland Clinic
ClinicalTrials.gov Identifier:	NCT00308204

Purpose

The purpose of this study is to investigate the efficacy of Raptiva (efalizumab) in the treatment of discoid lupus erythematosus (DLE). Discoid lupus erythematosus is a chronic disorder, which may lead to permanent and progressive loss of hair. Lupus is a condition of chronic inflammation cause by an autoimmune disease. Autoimmune diseases are illnesses which occur when the body's tissues are attacked by its own immune system. The immune system is a complex system within the body that is designed to fight infectious agents, for example, bacteria, and other foreign invaders.

One of the mechanisms that the immune system uses to fight infections is the production of antibodies. Patients with lupus produce abnormal antibodies in their blood that target tissues within their own body rather than foreign infectious agents. Lupus can cause disease of the skin, heart, lungs, kidneys, joints, and nervous system. When only the skin is involved, the condition is called discoid lupus erythematosus (DLE).

Raptiva (efalizumab) is a humanized immunoglobulin(a protein extract from blood which fights off infection-sometimes called "antibody"), which targets the immune cells that are activated in inflammation. Raptiva has been approved for use in the management of psoriasis at doses of 1mg/kg, but is not approved for the treatment of DLE.

Condition	Intervention	Phase
Discoid Lupus Erthematosus of the Scalp.	Drug: Raptiva (efalizumab)	Phase II

MedlinePlus related topics: Autoimmune Diseases Lupus

Drug Information available for: Efalizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:

A 10% increase in visualized hair count in the target region between baseline and week 24 as determined by macrophotography and validated computer assisted dot mapping technique.

Secondary Outcome Measures:

Rating of treatment benefit via use of global photographs of the vertex region assessed as an overall improvement from baseline.
Physician's global assessment (PGA) will be used to assess improvement of disease.

Estimated Enrollment:	10
Study Start Date:	March 2006

Detailed Description:

This is an open label study in which the subject will be given the medication Raptiva (efalizumab) and they will be taught to self-inject by the dermatology nurse or research doctor. The subject will be administering 0.7mg/kg at week one and 1mg/kg once a week thereafter until week 24. If the subject feels uncomfortable self-administering these injections, the subject may identify a caregiver to administer these injections for them. He or she will be taught to administer these injections by the dermatology nurse or research doctor.

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

adults with discoid lupus erythematosus with active area of disease involving at least 10% of scalp, confirmed by biopsy, bacterial and fungal culture negative.
ability to provide written informed consent and comply with study assessments for the full duration of the study.
adults 18 to 70 years of age.
if a female of childbearing potential, a negative pregnancy test and commitment to the use of two forms of effective contraception (birth control) for the duration of the study are necessary.
if a non-sterile male, commitment to the use of two forms of effective contraception (birth control) for the duration of the study is necessary.
Platelets >100,000

Exclusion Criteria:

subjects with known hypersensitivity to Raptiva (efalizumab) or any of its components
pregnant or lactating women
patients receiving immunosuppressive agents (not allowed 30 days or 5 half-live periods before Day 0, whichever is longer).
prior enrollment in the study
any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
participation in another simultaneous medical investigation or trial
history of malignancy in the last 10 years.
signs or symptoms of systemic lupus erythematosus.
have a history of active tuberculosis or are currently undergoing treatment for tuberculosis. A purified protein derivative (PPD) test or chest x-ray will be performed at the screening visit. Patients with a positive PPD test or chest x-ray will be excluded.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00308204

Locations

United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

The Cleveland Clinic

Investigators

Principal Investigator:

Wilma F Bergfeld, MD

Cleveland Clinic

More Information

Study ID Numbers:	ACD3433s
Study First Received:	March 28, 2006
Last Updated:	May 22, 2007
ClinicalTrials.gov Identifier:	NCT00308204
Health Authority:	United States: Food and Drug Administration

Keywords provided by The Cleveland Clinic:

discoid lupus
lupus
discoid lupus erythematosus
lupus of the scalp

Study placed in the following topic categories:

Autoimmune Diseases
Skin Diseases
Lupus Erythematosus, Systemic
Lupus Erythematosus, Cutaneous

Connective Tissue Diseases
Lupus Erythematosus, Discoid
Cutaneous lupus erythematosus

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 14, 2009